A survey of Australian prescribers’ views on the naming and substitution of biologicals

Author(s): Michael S Reilly, Esq, Stephen P Murby, FRSA

Author byline as per print journal: Stephen P Murby, FRSA; Michael S Reilly, Esq Introduction: As the number of biosimilar approvals in Australia increases, it is important to build on the existing regulatory framework to continue to bring high quality, safe and efficacious biosimilars to the widest number of patients most cost-effectively. As new policies regarding […]

Read more →